Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis PatientBenzinga • 03/10/22
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewsWire • 03/10/22
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's DiseaseGlobeNewsWire • 02/04/22
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology ConferenceGlobeNewsWire • 01/26/22
Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 MillionGlobeNewsWire • 01/24/22
Tiziana Life Sciences given nod for second patient to undergo multiple sclerosis treatmentProactive Investors • 01/10/22
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple SclerosisGlobeNewsWire • 01/10/22
Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor ConferenceGlobeNewsWire • 01/06/22
Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQGlobeNewsWire • 10/21/21
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of CapitalGlobeNewsWire • 10/19/21
Tiziana Life Sciences' half-term report reveals it has made progress on all frontsProactive Investors • 09/27/21
Tiziana Life Sciences half-term report reveals it has made progress on all frontsProactive Investors • 09/27/21
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021GlobeNewsWire • 09/24/21
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer TreatmentGlobeNewsWire • 09/07/21
Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciencesProactive Investors • 09/02/21